This study also showed that treating cultured EGFRM+ NSCLC cells with osimertinib resulted in AXL upregulation as well as interaction with EGFR and ERBB3, which in turn contributed to maintaining cell survival and to the emergence of osimertinib-tolerant cells. The gene discussed is ERBB3; the disease is non-small cell lung carcinoma.